Second-guessing FDA requests for safety data is a risky strategy in getting drug approval - even for new formulations of drugs that are already on the market. Last week the FDA declined to accept an NDA from Nastech Pharmaceutical Co. Inc. for a nasally administered formulation of scopolamine to treat motion sickness, after the company provided less safety data than the agency had requested.

According to CFO Andy